Wyeth-Ayerst Effexor XR Shows Efficacy In Long-Term GAD From Weeks 2-28
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A pivotal, 28-week trial of Wyeth-Ayerst’s Effexor XR (venlafaxine) in the long-term treatment of generalized anxiety disorder (GAD) showed that patients had statistically significant improvements versus placebo for all primary and secondary endpoints by week two, and that those improvements lasted throughout the study, investigators reported in the June 21 issue of the Journal of the American Medical Association.